New small molecule to prevent and treat heart problems in Duchenne muscular dystrophy
Official title: Novel small molecule for the prevention and treatment of DMD cardiomyopathy
Funded at Novomedix, INC. · NIH-11419291 · Data updated 2026-11-12
A new drug-like molecule is being tested in animal models to help protect the heart and muscles in Duchenne muscular dystrophy.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Novomedix, INC. NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project start | September 1, 2026 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $355,963 |
| NIH project number | 1R43HL182659-01A1 |
| Project ID | NIH-11419291 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be individuals with Duchenne muscular dystrophy and heart involvement suitable for future translation of the therapy (note: current work is preclinical in animal models).
✕Less likely to help
Patients without DMD or without cardiac involvement may not benefit from this preclinical study.
What this research studies
Duchenne muscular dystrophy is a serious condition that not only weakens muscles but also harms the heart. This project uses a mouse model of DMD and novel anti-fibrotic compounds to understand how reducing inflammation, cell death, and scarring in the heart might improve heart function. The goal is to identify how these compounds could prevent heart failure and improve quality of life for patients with DMD. Researchers will examine how the drug affects heart tissue, inflammation, and fibrosis in the diseased model. The overall aim is to translate these findings into safer and more effective treatments for people with DMD in the future.
Why it matters
Potential benefit: If successful, the research could lead to new heart-protective treatments for people with Duchenne muscular dystrophy.
How similar studies have gone: Preclinical studies with similar anti-fibrotic approaches have shown promise in reducing heart damage in disease models, but human effectiveness remains to be demonstrated.
Where this research is happening
-
Novomedix, INC.
San Diego, United States Active
Researchers
- Principal investigator: Swindlehurst, Cathy a — Novomedix, INC.
- Study coordinator: Swindlehurst, Cathy a
Related research
Other NIH-funded projects on the same topics.
-
Global bromocriptine trial for postpartum cardiomyopathy
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with peripartum cardiomyopathy.
-
Global Bromocriptine Add-on for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding the dopamine agonist bromocriptine to standard heart failure care helps postpartum women with a specific heart condition.
-
Global Bromocriptine Trial for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding bromocriptine to standard heart-failure care helps women with postpartum cardiomyopathy.
-
Bromocriptine as add-on therapy for postpartum cardiomyopathy across multiple sites
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with postpartum cardiomyopathy.
-
Global bromocriptine trial to help postpartum heart failure patients
A large international trial tests whether adding bromocriptine to standard heart failure treatment improves outcomes for new mothers with a specific pregnancy-related heart condition.
-
Global Bromocriptine Trial to Help Postpartum Heart Failure
A large international study will test whether adding bromocriptine to standard heart failure treatment helps women with postpartum cardiomyopathy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.